We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Hua Medicine

News List

Hua Medicine Announces 2021 Annual Results PharmaSources.com
March 17, 2022
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period").
Hua Medicine Announces 2020 Interim Results ACN Newswire
September 09, 2021
New Drug Application for a potential First in Class GKA dorzagliatin accepted by NMPA Expansion of indications for dorzagliatin strengthened R&D pipeline
Hua Medicine raises $117.4 M funding biospectrumasia
March 30, 2018
The financing is expected to fully fund the Company through completion of its two Phase 3 trials and commercial launch in China for Dorzagliatin.
Hua Medicine picks Hong Kong, S.A.R., China for IPO biospectrumasia
March 12, 2018
The offering could raise as much as $300 million.
Hua Medicine of Shanghai to Raise $200M to Support Novel Diabetes Drug biospace
January 16, 2018
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin